Evidence map›Paper›PMID 40376259›Full record

ArticleChina CDC weekly2025

Vaccination Status and Incidences of Measles, Mumps, and Rubella - Worldwide, 2014-2023.

Qianqian Liu, Qi Bi, Siyu Liu, Yuexin Xiu, Fuzhen Wang, Zundong Yin, Xiaoxue Liu

Abstract read
In one paragraph

Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qianqian LiuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Qi BiNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Siyu LiuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Yuexin XiuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Fuzhen WangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Zundong YinNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Xiaoxue LiuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Measles, mumps, and rubella remain significant global health threats despite being vaccine-preventable diseases. The World Health Organization aims to achieve regional elimination of measles and rubella by 2030, yet substantial disparities in vaccination coverage and disease incidence persist across regions. We analyzed global vaccination and disease data to provide evidence for optimizing immunization strategies. Methods: The study analyzed World Health Organization data on measles, mumps, and rubella from 2014-2023. Our analysis included vaccine types, recommended vaccination schedules, coverage rates, supplemental immunization activities, and disease incidence. We employed descriptive epidemiological methods for data synthesis and analysis. Results: All countries implemented ≥1 measles-containing vaccine dose, with 190 (97.9%) countries using a ≥2-dose schedule. Global 2nd dose of measles-containing vaccine coverage increased from 59% to 74% during the study period. High-income regions maintained >90% coverage, while the African Region reported the lowest coverage (70% for the 1st dose and 49% for the 2nd dose of measles-containing vaccine). Supplemental immunization activities helped address coverage gaps but required integration with routine immunization systems. Rubella vaccine was implemented in 90.2% of countries, while mumps vaccine adoption remained lower at 63.9%. The African Region experienced high incidence rates for both measles (551.8 per million) and rubella (21.9 per million). The COVID-19 pandemic disrupted vaccination coverage (3%-5% decline globally), with the African Region experiencing a post-pandemic U-shaped resurgence in cases. China's transition to the measles, mumps, and rubella vaccine has reduced mumps incidence to below 100 cases per million by 2020. Conclusions: While global control of measles, mumps, and rubella has progressed, inequities in vaccination coverage and pandemic-related disruptions threaten elimination goals. Strengthening routine immunization systems is critical. Achieving the World Health Organization's 2030 targets will require sustained investment in health systems and implementation of equity-focused innovations.

Indexed as

IncidenceMeaslesMember StatesMumpsRubellaVaccination

Identifiers

PMID40376259
PMCPMC12075482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.